Product image of Neupogen (Filgrastim) supplied by GNH India

Neupogen

Active Ingredient:
Filgrastim
Origin:
EU

Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as a sterile solution for intravenous and subcutaneous use. It stimulates neutrophil production and is used to reduce the duration of neutropenia in patients undergoing chemotherapy, bone‑marrow transplantation, or with congenital neutrophil disorders.

GNH India supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Amgen Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neupogen (filgrastim) acts on the hematopoietic system to support neutrophil recovery in several clinical settings.

  • Chemotherapy‑induced neutropenia: shortens the period of low neutrophil counts and reduces infection risk.
  • Aplastic anemia: promotes neutrophil production in patients with bone‑marrow failure.
  • Bone marrow transplantation: enhances engraftment and accelerates neutrophil recovery post‑transplant.
  • Congenital neutropenia: maintains adequate neutrophil levels in inherited neutrophil disorders.

How It Works

  • Filgrastim binds to the specific granulocyte‑colony stimulating factor (G‑CSF) receptor on hematopoietic progenitor cells in the bone marrow. This interaction activates intracellular signaling pathways that drive proliferation, differentiation, and functional activation of neutrophil precursors, leading to increased circulating neutrophil counts and improved innate immune defense.

Side Effects

Neupogen may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of symptoms are essential.

Common Side Effects

  • Bone pain: often mild to moderate, typically in the limbs or back.
  • Injection site reactions: redness, swelling, or discomfort at the administration site.
  • Fever: low‑grade temperature elevations.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Splenic rupture: sudden abdominal pain requiring immediate medical attention.
  • Acute respiratory distress syndrome (ARDS): severe breathing difficulty.
  • Severe allergic reactions: hives, swelling, or anaphylaxis.
  • Leukocytosis: excessively high white‑blood cell counts.
  • Capillary leak syndrome: rapid fluid shift causing low blood pressure.
  • Thromboembolic events: blood clots in veins or arteries.

Precautions & Warnings

Before using Neupogen, consider the following safety measures.

  • Renal impairment: adjust monitoring as reduced clearance may affect exposure.
  • Sickle cell disease: observe for vaso‑occlusive crises.
  • Prior splenectomy: increased vigilance for splenic complications.
  • Concurrent chemotherapy: coordinate timing to avoid overlapping toxicities.
  • Pediatric use: dose and response may differ; follow specialist guidance.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Avoid Interactions

Neupogen can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Corticosteroids: may blunt neutrophil response to filgrastim.
  • Chemotherapeutic agents with prolonged myelosuppression: can counteract the intended neutrophil recovery.

Moderate Interactions (Monitor Closely)

  • Antimicrobial agents (e.g., quinolones): may increase risk of bone pain.
  • Immunosuppressants (e.g., cyclosporine): monitor for additive effects on blood counts.
  • Live vaccines: reduced efficacy; consider timing of vaccination relative to filgrastim administration.

Frequently Asked Questions

Neupogen (filgrastim) is prescribed to reduce the duration and severity of neutropenia in patients receiving chemotherapy, those with aplastic anemia, individuals undergoing bone‑marrow transplantation, and patients with congenital neutropenia. By stimulating neutrophil production, it helps lower infection risk in these vulnerable groups.

Filgrastim mimics the natural granulocyte‑colony stimulating factor. It binds to G‑CSF receptors on bone‑marrow progenitor cells, activating signaling pathways that promote the proliferation, differentiation, and activation of neutrophil precursors, resulting in increased circulating neutrophils and enhanced immune defense.

The dose of Neupogen is individualized by the prescribing clinician based on the patient’s weight, indication, and treatment protocol. Healthcare professionals calculate the appropriate amount and administration schedule to achieve the desired neutrophil response while minimizing adverse effects.

Safety data for filgrastim in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss potential risks with the patient.

To request Neupogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Neupogen (filgrastim) is a recombinant form of human G‑CSF, similar in function to other agents such as pegfilgrastim or biosimilar filgrastim products. While pegfilgrastim offers a longer half‑life requiring fewer injections, Neupogen provides flexibility for dose adjustments and is often chosen for short‑term or pediatric use.

Neupogen must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it should be used promptly and not be re‑refrigerated.

Neupogen is given by intravenous infusion or subcutaneous injection, as directed by the healthcare provider. The route, volume, and frequency depend on the clinical indication and the patient’s response. Proper aseptic technique and correct dosing equipment are essential for safe administration.

Serious risks include splenic rupture, acute respiratory distress syndrome, severe allergic reactions (anaphylaxis), leukocytosis, capillary leak syndrome, and thromboembolic events. Patients should be monitored for sudden abdominal pain, breathing difficulties, rash, or unexplained swelling, and seek immediate medical attention if these occur.

Neupogen is contraindicated in patients with known hypersensitivity to filgrastim or any component of the formulation. Caution is also advised for individuals with a history of splenic rupture, uncontrolled leukemia, or those receiving certain high‑dose chemotherapies that may negate its benefit.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Filgrastim

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT